CLYM

insider transactions

Climb Bio, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-142.9K

7.1K buy · 150.0K sell

Net value · 365d

-$854.5K

$24.9K in · $879.4K out

Sentiment · 365d

Net selling

3% buying · 97% selling

Open-market trades · 365d

7.1K buy · 150.0K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 5, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund II, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$0

40.0K sh

Own New
Grant·A
Jun 5, 26

Andrew David Levin

Director

$0

40.0K sh

Own New
Grant·A
Jun 5, 26

Kimberlee C Drapkin

Director

$0

40.0K sh

Own New
Grant·A
Jun 5, 26

Douglas E Williams

Director

$0

40.0K sh

Own New
Grant·A
Jun 5, 26

Alexander Cumbo

Director

$0

40.0K sh

Own New
Grant·A
Jun 5, 26

Stephen Basil Thomas

Director

$0

40.0K sh

Own New
Grant·A
Jun 5, 26

Judith Dunn

Director

$0

40.0K sh

Own New
Grant·A
Apr 29, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund II, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$20.0M

2.1M sh · $9.50

Own +10%
Sell·S
Feb 26, 26

Stephen Basil Thomas

Director · 10b5-1

$114.3K

16.3K sh · $7.01

Own -10%
Sell·S
Feb 25, 26

Stephen Basil Thomas

Director · 10b5-1

$236.0K

33.7K sh · $7.00

Own -16%
Sell·S
Feb 13, 26

Stephen Basil Thomas

Director · 10b5-1

$58.1K

10.0K sh · $5.81

Own -5%
Sell·S
Feb 12, 26

Stephen Basil Thomas

Director · 10b5-1

$471.0K

90.0K sh · $5.23

Own -30%
Grant·A
Jan 6, 26

Perrin Megan Wilson

Chief Business Officer

$0

300.0K sh

Own New
Grant·A
Jan 6, 26

Cindy Driscoll KEY

Senior Vice President, Finance

$0

100.0K sh

Own New
Grant·A
Jan 6, 26

Susan Altschuller KEY

Chief Financial Officer

$0

142.5K sh

Own New
Buy·P
Jan 5, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund II, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$24.9K

7.1K sh · $3.50

Own +0%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 5, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund II, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Grant A	40.0K	New	—	$0
Jun 5, 2026	Andrew David Levin	Director	Grant A	40.0K	New	—	$0
Jun 5, 2026	Kimberlee C Drapkin	Director	Grant A	40.0K	New	—	$0
Jun 5, 2026	Douglas E Williams	Director	Grant A	40.0K	New	—	$0
Jun 5, 2026	Alexander Cumbo	Director	Grant A	40.0K	New	—	$0
Jun 5, 2026	Stephen Basil Thomas	Director	Grant A	40.0K	New	—	$0
Jun 5, 2026	Judith Dunn	Director	Grant A	40.0K	New	—	$0
Apr 29, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund II, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Grant A	2.1M	+10%	$9.50	$20.0M
Feb 26, 2026	Stephen Basil Thomas 10b5-1	Director	Sell S	16.3K	-10%	$7.01	$114.3K
Feb 25, 2026	Stephen Basil Thomas 10b5-1	Director	Sell S	33.7K	-16%	$7.00	$236.0K
Feb 13, 2026	Stephen Basil Thomas 10b5-1	Director	Sell S	10.0K	-5%	$5.81	$58.1K
Feb 12, 2026	Stephen Basil Thomas 10b5-1	Director	Sell S	90.0K	-30%	$5.23	$471.0K
Jan 6, 2026	Perrin Megan Wilson	Chief Business Officer	Grant A	300.0K	New	—	$0
Jan 6, 2026	Cindy Driscoll KEY	Senior Vice President, Finance	Grant A	100.0K	New	—	$0
Jan 6, 2026	Susan Altschuller KEY	Chief Financial Officer	Grant A	142.5K	New	—	$0
Jan 5, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund II, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Buy P	7.1K	+0%	$3.50	$24.9K

About CLYM insider trading

This page tracks insider transactions for Climb Bio, Inc. (CLYM) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.